within Pharmacolibrary.Drugs.ATC.G;

model G02AB03
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.62,
    Cl             = 0.00023333333333333333,
    adminDuration  = 600,
    adminMass      = 0.25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00155,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G02AB03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ergometrine (also known as ergonovine) is an ergot alkaloid used primarily to prevent or treat postpartum hemorrhage by inducing uterine contractions. It is no longer routinely used for labor induction due to safety concerns but remains approved or available for postpartum use in various countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult women, single oral or intravenous dose, nonpregnant and postpartum individuals.</p><h4>References</h4><ol><li><p>de Groot, AN, et al., &amp; van Roosmalen, J (1994). Pharmacokinetics and bioavailability of oral ergometrine in male volunteers. <i>Biopharmaceutics &amp; drug disposition</i> 15(1) 65–73. DOI:<a href=&quot;https://doi.org/10.1002/bdd.2510150106&quot;>10.1002/bdd.2510150106</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8161717/&quot;>https://pubmed.ncbi.nlm.nih.gov/8161717</a></p></li><li><p>de Groot, AN (1996). The role of oral (methyl)ergometrine in the prevention of postpartum haemorrhage. <i>European journal of obstetrics, gynecology, and reproductive biology</i> 69(1) 31–36. DOI:<a href=&quot;https://doi.org/10.1016/0301-2115(95)02531-6&quot;>10.1016/0301-2115(95)02531-6</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8909954/&quot;>https://pubmed.ncbi.nlm.nih.gov/8909954</a></p></li><li><p>de Groot, AN, et al., &amp; van Roosmalen, J (1995). Comparison of the bioavailability and pharmacokinetics of oral methylergometrine in men and women. <i>International journal of clinical pharmacology and therapeutics</i> 33(6) 328–332. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7582383/&quot;>https://pubmed.ncbi.nlm.nih.gov/7582383</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G02AB03;
